Health Evaluation in African Americans Using RAS Therapy
Maneno muhimu
Kikemikali
Maelezo
This study will assess if Telmisartan, an FDA approved blood pressure medication, may also have beneficial effects on Alzheimer's disease (AD) prevention in African Americans, who are at high risk for Alzheimer's disease. Blood pressure medications known as angiotensin-receptor blockers have been associated with reduced risk of Alzheimer's in Caucasians because they act on the renin-angiotensin system (RAS), a key regulator of blood pressure in the body and the brain. The drugs appear to slow the progression of the disease by affecting flow of blood and the amount of plaque in the brain, but these benefits have not been tested in African Americans. The investigator will evaluate if Telmisartan is able to influence the renin-angiotensin system in the brain and produce favorable effects on brain blood flow and enzymes that cause the brain plaques in Alzheimer's disease.The investigator will assess the mechanism by which Telmisartan modifies the brain renin angiotensin system, cerebrospinal fluid amyloid-β, cerebral blood flow (CBF) and inflammatory markers in hypertensive African Americans.
Tarehe
Imethibitishwa Mwisho: | 04/30/2019 |
Iliyowasilishwa Kwanza: | 06/09/2015 |
Uandikishaji uliokadiriwa Uliwasilishwa: | 06/10/2015 |
Iliyotumwa Kwanza: | 06/14/2015 |
Sasisho la Mwisho Liliwasilishwa: | 05/30/2019 |
Sasisho la Mwisho Lilichapishwa: | 06/02/2019 |
Tarehe halisi ya kuanza kwa masomo: | 03/31/2015 |
Tarehe ya Kukamilisha Msingi iliyokadiriwa: | 06/29/2020 |
Tarehe ya Kukamilisha Utafiti: | 06/29/2020 |
Hali au ugonjwa
Uingiliaji / matibabu
Drug: Telmisartan 20mg
Drug: Telmisartan 40mg
Drug: Placebo
Awamu
Vikundi vya Arm
Mkono | Uingiliaji / matibabu |
---|---|
Experimental: Telmisartan 20mg African American subjects with hypertension and at high risk for Alzheimer's disease will be randomly assigned to receive Telmisartan 20mg once a day orally. | Drug: Telmisartan 20mg Subjects will be given 20 mg of Telmisartan to be taken orally once a day before bedtime. Subjects will be on Telmisartan 20mg for a duration of 8 months. |
Experimental: Telmisartan 40mg African American subjects with hypertension and at high risk for Alzheimer's disease will be randomly assigned to receive Telmisartan 40mg once a day orally. | Drug: Telmisartan 40mg Subjects will be given 40 mg of Telmisartan to be taken orally once a day before bedtime. Subjects will be on Telmisartan 40mg for a duration of 8 months. |
Placebo Comparator: Placebo African American subjects with hypertension and at high risk for Alzheimer's disease will be randomly assigned to receive placebo once a day orally. | Drug: Placebo Subjects will be given placebo to be taken orally once a day before bedtime. Subjects will be on placebo for a duration of 8 months. |
Vigezo vya Kustahiki
Zama zinazostahiki Kujifunza | 30 Years Kwa 30 Years |
Jinsia Inastahiki Kujifunza | All |
Hupokea Wajitolea wa Afya | Ndio |
Vigezo | Inclusion Criteria: 1. Treated hypertension (systolic blood pressure ≥ 110 mmHg systolic and ≤ 170 mmHg 2. Parent or biological family member with Alzheimer's disease 3. African American Exclusion Criteria: 1. Mean resting blood pressure ≥110 and ≤ 170 mmHg systolic 2. Currently in another investigational drug study 3. Current use of renin-angiotensin acting medication 4. Potassium >5.5 meq/dl at baseline 5. Creatinine >1.99 mg/dl at baseline 6. History of stroke 7. Dementia 8. Baseline Montreal Cognitive Assessment score <27 9. Contraindication for lumbar puncture or magnetic resonance imaging 10. Heart failure 11. Diabetes Types I and II 12. Pregnant or nursing women |
Matokeo
Hatua za Matokeo ya Msingi
1. Change in concentration of cerebrospinal fluid angiotensin metabolites [Baseline, 8 months from baseline]
Hatua za Matokeo ya Sekondari
1. Change in levels of plasma angiotensinogen [Baseline, 4 months from baseline]
2. Change in levels of plasma angiotensinogen [4 months from baseline, 8 months from baseline]
3. Change in levels of plasma renin [Baseline, 4 months from baseline]
4. Change in levels of plasma renin [4 months from baseline, 8 months from baseline]
5. Change in levels of plasma angiotensin converting enzyme [Baseline, 4 months from baseline]
6. Change in levels of plasma angiotensin converting enzyme [4 months from baseline, 8 months from baseline]
7. Change in levels of plasma aldosterone [Baseline, 4 months from baseline]
8. Change in levels of plasma aldosterone [4 months from baseline, 8 months from baseline]
9. Change in levels of cerebrospinal fluid amyloid β42 [Baseline, 8 months from baseline]
10. Change in levels of cerebrospinal fluid T-tau [Baseline, 8 months from baseline]
11. Change in levels of cerebrospinal fluid P-tau [Baseline, 8 months from baseline]
12. Change in arterial function [Baseline, 8 months from baseline]
13. Flanker Inhibitory Control and Attention Test [Baseline, 8 months from baseline]
14. Set-shifting Test [Baseline, 8 months from baseline]
15. Spatial 1-Back Test [Baseline, 8 months from baseline]
16. Montreal Cognitive Assessment [Baseline, 8 months from baseline]
17. Mini Mental State Examination (MMSE) [Baseline, 8 months from baseline]
18. Wechsler Adult Intelligence Scale (WAIS)-Working Memory subtests [Baseline, 8 months from baseline]
19. Wechsler Memory Scale-III Faces Test [Baseline, 8 months from baseline]
20. Wechsler Memory Scale-Revised Logical Memory Test [Baseline, 8 months from baseline]
21. Rey Auditory Verbal Learning Test [Baseline, 8 months from baseline]
22. Arterial Spin Labeling-Magnetic Resonance Imaging [Baseline, 8 months from baseline]
23. Structural Magnetic Resonance Imaging and White Matter Hyperintensities [Baseline, 8 months from baseline]